TARDBP Antibodies

Santa Cruz Biotechnology features a diverse variety of TARDBP monoclonal antibodies for investigating TAR DNA-binding protein 43 (TARDBP) in various cellular processes. TARDBP monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). TARDBP is crucial for regulating gene expression and maintaining RNA stability, playing a significant role in neuronal health and function. Dysregulation of TARDBP has been implicated in neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), making it a vital target for research. Understanding TARDBP mechanisms can provide insights into disease pathology and potential therapeutic strategies. Researchers worldwide rely on TARDBP monoclonal antibodies to advance their studies in RNA processing and regulation. TARDBP monoclonal antibodies enable detailed examination of protein localization and interactions in cellular pathways. Current research utilizing TARDBP monoclonal antibodies continues to reveal new aspects of neurodegenerative disease progression. Santa Cruz Biotechnology monoclonal antibodies support breakthrough discoveries in neuroscience and disease research, advancing our understanding of critical cellular processes.